이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors

2026년 11월 13일 업데이트: Pfizer

A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-08165784 MONOTHERAPY AND COMBINATIONS IN PARTICIPANTS WITH PIK3CA-MUTATED ADVANCED OR METASTATIC SOLID TUMORS

The purpose of this study is to learn about the safety and effects of the study medicine (called PF-08165784) when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment given to stop the growth of cancer. This study also aims to find the best amount of study medication that can be given to patients.

This study is seeking participants with a specific type of breast cancer called hormone receptor-positive (HR+), HER2- negative (HER2-) breast cancer, or colorectal cancer (cancer of the colon or rectum), that has a change (mutation) in a gene called PIK3CA. The cancer must be advanced or metastatic, meaning it has spread to other parts of the body or cannot be completely removed with surgery.

All participants in this study will take the study medication (PF-08165784) as a tablet by mouth. The participant may take the medicine at the study clinic during study visits or at home. Treatment will be given in 28-day cycles and will continue for as long as the participant remains in the study. Depending on which part of the study participants are enrolled into, they will receive the study medication (PF-08165784) alone or in combination with other anti-cancer medications.

연구 개요

연구 유형

중재적

등록 (추정된)

268

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Arkansas
      • Fayetteville, Arkansas, 미국, 72703
        • Highlands Oncology Group, PA
      • Rogers, Arkansas, 미국, 72758
        • Highlands Oncology Group, PA
      • Springdale, Arkansas, 미국, 72762
        • Highlands Oncology Group, PA
    • Michigan
      • Grand Rapids, Michigan, 미국, 49546
        • START Midwest, LLC
      • San Juan, 푸에르토 리코, 00935
        • Pan American Center for Oncology Trials, LLC- Hospital Oncológico Office

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • 18 years of age or older
  • Advanced or metastatic cancer of the breast or colon Part 1A, IB, and 1C: HR+/HER2- advanced or metastatic breast cancer with disease progression after at least 1 line of treatment with an endocrine therapy and CDK4/6 inhibitor in the advanced or metastatic setting and received no more than 1 line of prior cytotoxic and/or 1 line of prior ADC therapy in the metastatic setting Part 1D: Metastatic or advanced colorectal cancer with at least having received chemotherapy and/or targeted therapy if appropriate Part 2A: HR+/HER2- advanced or metastatic breast cancer with no prior systemic therapy or chemotherapy for advanced or metastatic disease
  • PIK3CA mutation
  • Archived tumor specimen or fresh tumor biopsy
  • Measurable disease
  • ECOG performance status 0 or 1

Exclusion Criteria:

  • Active or clinically significant dermatologic conditions
  • Active malignancy within 3 years prior to enrollment
  • Advanced/metastatic, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term
  • Major surgery or radiation therapy within 3 weeks prior to study entry
  • Prior irradiation to >25% of the bone marrow
  • Active or history of pneumonitis/interstitial lung disease requiring corticosteroids
  • Unmanageable ascites
  • Prior treatment with PI3K/AKT/mTOR pathway inhibitors may be permitted in certain study cohorts and excluded in others, as specified by the study protocol.
  • Renal impairment
  • Hepatic dysfunction
  • Hematologic abnormalities
  • Uncontrolled diabetes
  • Cardiac abnormalities
  • Active or history of clinically significant GI or inflammatory GI disease
  • Other unacceptable abnormalities or prohibited therapies as defined by protocol

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 순차적 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Part 1 Dose Escalation Cohort 1A

PF-08165784 monotherapy dose escalation for participants with advanced or metastatic BC at different doses of the study drug

Taken by mouth (PO)

실험적: Part 1 Dose Escalation Cohort 1B

Combination (PF-08165784 + fulvestrant) dose escalation for participants with advanced or metastatic BC, at different doses of the study drug

Selective Estrogen Receptor Degrader (SERD)

다른 이름들:
  • 파슬로덱스

Taken by mouth (PO)

실험적: Part 1 Dose Escalation Cohort 1C

Combination (PF-08165784 + fulvestrant + atirmociclib) dose escalation for participants with advanced or metastatic BC, at different doses of the study drug

Selective Estrogen Receptor Degrader (SERD)

다른 이름들:
  • 파슬로덱스

Taken by mouth (PO)

Selective CDK4 inhibitor

다른 이름들:
  • PF-07220060
실험적: Part 1 Dose Escalation Cohort 1D

Combination (PF-08165784 + cetuximab) dose escalation for participants with advanced or metastatic CRC at different doses of the study drug

Monoclonal antibody (EGFR inhibitor)

다른 이름들:
  • 얼비툭스

Taken by mouth (PO)

실험적: Part 2 Dose Optimization/Expansion Cohort 2A

Combination (PF-08165784 + letrozole + atirmociclib) dose optimization/expansion for participants with advanced or metastatic BC, at different doses of the study drug

Taken by mouth (PO)

Selective CDK4 inhibitor

다른 이름들:
  • PF-07220060

Nonsteroidal aromatase inhibitor

다른 이름들:
  • 페마라

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Part 1 (Dose Escalation): Number of participants with Dose-Limiting Toxicities (DLT)
기간: Baseline up to 28 days

Any adverse events that are attributable to one, the other, or both study treatments, occurring in the DLT observation period are considered DLTs, excluding toxicities clearly due to underlying disease or extraneous causes.

Baseline up to 28 days
Part 1 (Dose Escalation): Number of participants with laboratory abnormalities
기간: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first

Number of participants with laboratory test abnormalities.

From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
Part 1 (Dose Escalation): Incidence of Adverse Events (AEs)
기간: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first

An adverse event (AE) was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship to it.

From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
Part 2 (Dose Expansion): Objective Response Rate (ORR)
기간: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

ORR defined as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1).

Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

2차 결과 측정

결과 측정
측정값 설명
기간
Part 2 (Dose Expansion): Number of participants with laboratory abnormalities
기간: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first

Number of participants with laboratory test abnormalities.

From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
Part 2 (Dose Expansion): Incidence of Adverse Events (AEs)
기간: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first

An adverse event (AE) was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship to it.

From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
Part 1 & Part 2: Disease Control Rate (DCR) as per RECIST v1.1
기간: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

DCR is defined as the proportion of participants with CR or PR with confirmation, or Stable Disease (SD) per RECIST version 1.1.

Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
Part 1 & Part 2: Clinical Benefit Rate (CBR) as per RECIST v1.1
기간: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

CBR is defined as the percentage of participants with a best overall response of CR or PR at any time before Progressive Disease (PD), or non-CR/non-PD or SD for at least 24 weeks from start date of treatment and prior to PD, relative to the appropriate analysis set.

Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
Part 1 & Part 2: Duration of Response (DOR) as per RECIST v1.1
기간: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

DOR is defined as the time from first documentation of CR or PR to date of first documentation of PD or death due to any cause.

Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
Part 1 & Part 2: Progression-Free Survival (PFS) as per RECIST v1.1
기간: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

PFS is defined as time from start date of treatment to the date of first documentation of PD or death due to any cause.

Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
Part 1 & Part 2: Time to Response (TTR) as per RECIST v1.1
기간: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

TTR is defined as the time from start date of treatment to first documentation of CR or PR.

Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
Part 2: Overall Survival (OS)
기간: Up to approximately 2 years

OS is defined as time from from start date of treatment to the date of death due to any cause

Up to approximately 2 years
Part 1: Objective Response Rate (ORR) as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
기간: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

ORR is defined as the percentage of participants in the analysis population having a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST v1.1.

Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
Part 1: Maximum Observed Serum Concentration (Cmax) & Trough Concentration (Ctrough)
기간: Baseline through end of Cycle 1 (each cycle is 28 days)

Evaluate the single and multiple dose PK of PF-08165784 as monotherapy, or in combination with other anti-tumor agents.

Baseline through end of Cycle 1 (each cycle is 28 days)
Part 1: Time to Reach Maximum Observed Serum Concentration (Tmax)
기간: Baseline through end of Cycle 1 (each cycle is 28 days)

Evaluate the single and multiple dose PK of PF-08165784 as monotherapy, or in combination with other anti-tumor agents.

Baseline through end of Cycle 1 (each cycle is 28 days)
Part 1: Area Under the Curve (AUC) from Time Zero to Last Quantifiable Concentration (AUClast)
기간: Baseline through end of Cycle 1 (each cycle is 28 days)

Evaluate the single and multiple dose PK of PF-08165784 as monotherapy, or in combination with other anti-tumor agents.

Baseline through end of Cycle 1 (each cycle is 28 days)
Part 1: Effect of Food on Cmax
기간: Baseline through end of Cycle 1 (each cycle is 28 days)

Evaluate the effect of food on Cmax of PF-08165784 as monotherapy

Baseline through end of Cycle 1 (each cycle is 28 days)
Part 1: Effect of Food on Tmax
기간: Baseline through end of Cycle 1 (each cycle is 28 days)

Evaluate the effect of food on Tmax of PF-08165784 as monotherapy

Baseline through end of Cycle 1 (each cycle is 28 days)
Part 1: Effect of Food on AUClast
기간: Baseline through end of Cycle 1 (each cycle is 28 days)

Evaluate the effect of food on AUClast of PF-08165784 as monotherapy

Baseline through end of Cycle 1 (each cycle is 28 days)
Part 2 (Dose Expansion): Pre- and post-dose concentrations of PF-08165784
기간: Baseline through end of Cycle 1 (each cycle is 28 days)

Evaluate the pre- and post-dose concentrations of PF-08165784

Baseline through end of Cycle 1 (each cycle is 28 days)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: Pfizer CT.gov Call Center, Pfizer

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 11월 9일

기본 완료 (추정된)

2030년 3월 22일

연구 완료 (추정된)

2032년 3월 21일

연구 등록 날짜

최초 제출

2026년 10월 20일

QC 기준을 충족하는 최초 제출

2026년 10월 20일

처음 게시됨 (실제)

2026년 10월 27일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 18일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 13일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다